JP2010526069A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010526069A5 JP2010526069A5 JP2010506316A JP2010506316A JP2010526069A5 JP 2010526069 A5 JP2010526069 A5 JP 2010526069A5 JP 2010506316 A JP2010506316 A JP 2010506316A JP 2010506316 A JP2010506316 A JP 2010506316A JP 2010526069 A5 JP2010526069 A5 JP 2010526069A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- hetero
- compound
- cyclo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 23
- 125000003118 aryl group Chemical group 0.000 claims 18
- 125000000217 alkyl group Chemical group 0.000 claims 14
- 229910052739 hydrogen Inorganic materials 0.000 claims 14
- 239000001257 hydrogen Substances 0.000 claims 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 12
- 125000001072 heteroaryl group Chemical group 0.000 claims 12
- 125000005842 heteroatom Chemical group 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 8
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 8
- 125000003342 alkenyl group Chemical group 0.000 claims 8
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 102000009389 Prostaglandin D receptors Human genes 0.000 claims 5
- 108050000258 Prostaglandin D receptors Proteins 0.000 claims 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 125000002947 alkylene group Chemical group 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 230000004054 inflammatory process Effects 0.000 claims 4
- 102000005962 receptors Human genes 0.000 claims 4
- 108020003175 receptors Proteins 0.000 claims 4
- 201000001320 Atherosclerosis Diseases 0.000 claims 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 3
- 208000000094 Chronic Pain Diseases 0.000 claims 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims 3
- 206010010741 Conjunctivitis Diseases 0.000 claims 3
- 208000011231 Crohn disease Diseases 0.000 claims 3
- 201000004624 Dermatitis Diseases 0.000 claims 3
- 206010012438 Dermatitis atopic Diseases 0.000 claims 3
- 206010016654 Fibrosis Diseases 0.000 claims 3
- 206010028735 Nasal congestion Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 208000002193 Pain Diseases 0.000 claims 3
- 201000004681 Psoriasis Diseases 0.000 claims 3
- 206010037660 Pyrexia Diseases 0.000 claims 3
- 206010039085 Rhinitis allergic Diseases 0.000 claims 3
- 206010040047 Sepsis Diseases 0.000 claims 3
- 208000007536 Thrombosis Diseases 0.000 claims 3
- 206010052779 Transplant rejections Diseases 0.000 claims 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 3
- 206010052568 Urticaria chronic Diseases 0.000 claims 3
- 208000036142 Viral infection Diseases 0.000 claims 3
- 201000010105 allergic rhinitis Diseases 0.000 claims 3
- 208000006673 asthma Diseases 0.000 claims 3
- 201000008937 atopic dermatitis Diseases 0.000 claims 3
- 208000010668 atopic eczema Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 201000005547 chronic conjunctivitis Diseases 0.000 claims 3
- 208000037976 chronic inflammation Diseases 0.000 claims 3
- 208000024376 chronic urticaria Diseases 0.000 claims 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 230000004761 fibrosis Effects 0.000 claims 3
- 238000011010 flushing procedure Methods 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 230000009385 viral infection Effects 0.000 claims 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 2
- 125000006729 (C2-C5) alkenyl group Chemical group 0.000 claims 2
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 claims 2
- 125000006591 (C2-C6) alkynylene group Chemical group 0.000 claims 2
- 125000006532 (C3-C5) alkyl group Chemical group 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 239000003246 corticosteroid Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 125000004474 heteroalkylene group Chemical group 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 229940124003 CRTH2 antagonist Drugs 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 229940125715 antihistaminic agent Drugs 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 229940124748 beta 2 agonist Drugs 0.000 claims 1
- 229910052796 boron Inorganic materials 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 229960000265 cromoglicic acid Drugs 0.000 claims 1
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 claims 1
- 210000004392 genitalia Anatomy 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 0 **c1c(CCCCC2)c2c(*)c(*)c1*C1=CC=CI(CI*)=C1 Chemical compound **c1c(CCCCC2)c2c(*)c(*)c1*C1=CC=CI(CI*)=C1 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92754507P | 2007-05-02 | 2007-05-02 | |
| US60/927,545 | 2007-05-02 | ||
| PCT/US2008/005611 WO2008137027A2 (en) | 2007-05-02 | 2008-05-01 | Compounds as crth2 and/or pgd2 receptors modulators and their use for treating asthma and allergic inflammation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010526069A JP2010526069A (ja) | 2010-07-29 |
| JP2010526069A5 true JP2010526069A5 (enExample) | 2011-06-16 |
| JP5537417B2 JP5537417B2 (ja) | 2014-07-02 |
Family
ID=39619158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010506316A Expired - Fee Related JP5537417B2 (ja) | 2007-05-02 | 2008-05-01 | Ｃｒｔｈ２及び／又はｐｇｄ２受容体調節物質としての化合物、並びにぜん息及びアレルギー性炎症を治療するためのその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7960567B2 (enExample) |
| EP (1) | EP2164828B1 (enExample) |
| JP (1) | JP5537417B2 (enExample) |
| AU (1) | AU2008248201B2 (enExample) |
| CA (1) | CA2685215C (enExample) |
| ES (1) | ES2402987T3 (enExample) |
| MX (1) | MX2009011412A (enExample) |
| WO (1) | WO2008137027A2 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101663279A (zh) * | 2007-01-19 | 2010-03-03 | 阿迪生物科学公司 | Mek抑制剂 |
| CN101903338A (zh) * | 2007-12-19 | 2010-12-01 | 安姆根有限公司 | 用作炎症调节剂的苯基乙酸衍生物 |
| EP2257524B1 (en) | 2008-02-01 | 2016-01-06 | Brickell Biotech, Inc. | N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors |
| WO2009102893A2 (en) | 2008-02-14 | 2009-08-20 | Amira Pharmaceuticals, Inc. | CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 receptors |
| US8497381B2 (en) | 2008-02-25 | 2013-07-30 | Panmira Pharmaceuticals, Llc | Antagonists of prostaglandin D2 receptors |
| US8426449B2 (en) | 2008-04-02 | 2013-04-23 | Panmira Pharmaceuticals, Llc | Aminoalkylphenyl antagonists of prostaglandin D2 receptors |
| EP2826774B1 (en) * | 2008-06-25 | 2016-05-25 | Array Biopharma, Inc. | Intermediates for 6-substituted phenoxychroman carboxylic acid derivatives |
| CA2729292C (en) | 2008-07-03 | 2013-09-03 | Amira Pharmaceuticals, Inc. | Phenoxyphenyl sulfide, sulfinyl and sulfonyl antagonists of prostaglandin d2 receptors |
| JP5394487B2 (ja) * | 2008-07-15 | 2014-01-22 | エフ．ホフマン−ラ ロシュ アーゲー | アミノテトラヒドロインダゾロ酢酸 |
| JP5394488B2 (ja) * | 2008-07-15 | 2014-01-22 | エフ．ホフマン−ラ ロシュ アーゲー | アミノテトラヒドロインダゾロ酢酸 |
| GB2463788B (en) | 2008-09-29 | 2010-12-15 | Amira Pharmaceuticals Inc | Heteroaryl antagonists of prostaglandin D2 receptors |
| WO2010039977A2 (en) | 2008-10-01 | 2010-04-08 | Amira Pharmaceuticals, Inc. | Heteroaryl antagonists of prostaglandin d2 receptors |
| US8524748B2 (en) | 2008-10-08 | 2013-09-03 | Panmira Pharmaceuticals, Llc | Heteroalkyl biphenyl antagonists of prostaglandin D2 receptors |
| GB2465062B (en) | 2008-11-06 | 2011-04-13 | Amira Pharmaceuticals Inc | Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors |
| US8383654B2 (en) | 2008-11-17 | 2013-02-26 | Panmira Pharmaceuticals, Llc | Heterocyclic antagonists of prostaglandin D2 receptors |
| EP2379535B1 (en) * | 2008-12-22 | 2016-06-15 | Array Biopharma Inc. | 7-phenoxychroman carboxylic acid derivatives |
| CA2747419C (en) | 2009-01-12 | 2014-07-08 | Icagen, Inc. | Sulfonamide derivatives |
| SG178109A1 (en) | 2009-07-31 | 2012-03-29 | Panmira Pharmaceuticals Llc | Ophthalmic pharmaceutical compositions of dp2 receptor antagonists |
| CN102596902A (zh) | 2009-08-05 | 2012-07-18 | 潘米拉制药公司 | Dp2拮抗剂及其用途 |
| WO2011116277A1 (en) * | 2010-03-19 | 2011-09-22 | Oxygen Biotherapeutics, Inc. | Perfluorocarbon eye cream formulations |
| ES2532356T3 (es) | 2010-07-09 | 2015-03-26 | Pfizer Limited | N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje |
| US8513309B2 (en) | 2010-10-01 | 2013-08-20 | Oxygen Biotherapeutics, Inc. | Perfluorocarbons for use in treating pruritus |
| EP2457900A1 (en) | 2010-11-25 | 2012-05-30 | Almirall, S.A. | New pyrazole derivatives having CRTh2 antagonistic behaviour |
| US8471030B2 (en) | 2010-12-06 | 2013-06-25 | Orochem Technologies Inc. | Purification of montelukast using simulated moving bed |
| CN103204822B (zh) | 2012-01-17 | 2014-12-03 | 上海科州药物研发有限公司 | 作为蛋白激酶抑制剂的苯并噁唑化合物及其制备方法和用途 |
| TWI520962B (zh) | 2012-06-29 | 2016-02-11 | As the c-Met tyrosine kinase inhibitors novel fused pyridine derivatives | |
| CN104507930B (zh) * | 2012-06-29 | 2017-10-10 | 贝达药业股份有限公司 | 作为c‑Met酪氨酸激酶抑制剂的新型稠合吡啶衍生物 |
| AR091731A1 (es) * | 2012-07-19 | 2015-02-25 | Merck Sharp & Dohme | Antagonistas del receptor de mineralocorticoides |
| CN104870422B (zh) * | 2012-10-31 | 2019-03-15 | 富士胶片富山化学株式会社 | 胺衍生物或其盐 |
| RU2506259C1 (ru) * | 2012-12-04 | 2014-02-10 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Ярославский государственный университет им. П.Г. Демидова" | Способ получения 4-{4-амино-2-хлоро-5-[(5-хлоро-2-метил-1н-бензимидазол-6-ил)амино]фенокси}бензойной кислоты |
| CN103910682B (zh) * | 2013-11-28 | 2016-03-02 | 大连理工大学 | 一种基于邻苯二胺环化的苯并咪唑类化合物制备方法 |
| MX383376B (es) * | 2015-03-24 | 2025-03-13 | Shanghai Yingli Pharm Co Ltd | Derivado de un anillo condensado y método de preparación, compuesto intermedio, composición farmacéutica y uso del mismo. |
| JP2022540200A (ja) | 2019-07-11 | 2022-09-14 | エスケイプ・バイオ・インコーポレイテッド | Ｌｒｒｋ２阻害剤としてのインダゾールおよびアザインダゾール |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0753725B2 (ja) * | 1987-10-08 | 1995-06-07 | 富山化学工業株式会社 | ４ｈ―１―ベンゾピラン―４―オン誘導体およびその塩、それらの製造法並びにそれらを含有する抗炎症剤 |
| JPH0283376A (ja) * | 1988-09-19 | 1990-03-23 | Pfizer Pharmaceut Co Ltd | ベンゾオキサゾロン誘導体および抗アレルギー又は抗炎症組成物 |
| US5849780A (en) | 1992-01-30 | 1998-12-15 | Sanofi | 1-benzenesulfonyl-1-1,3-dihydroindol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present |
| US5545669A (en) | 1994-06-02 | 1996-08-13 | Adams; Jerry L. | Anti-inflammatory compounds |
| US5929250A (en) | 1997-01-23 | 1999-07-27 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
| US6297239B1 (en) * | 1997-10-08 | 2001-10-02 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| CA2322742A1 (en) * | 1998-03-13 | 1999-09-23 | Merck Frosst Canada & Co./Merck Frosst Canada & Cie | Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment |
| JP2000026430A (ja) * | 1998-07-02 | 2000-01-25 | Taisho Pharmaceut Co Ltd | ２、５、６−置換ベンズイミダゾール化合物誘導体 |
| CN1515548A (zh) * | 1999-03-01 | 2004-07-28 | �Ʒ� | 用作甲状腺受体配体的草氨酸及衍生物 |
| US20020072530A1 (en) | 2000-02-01 | 2002-06-13 | Bing-Yan Zhu | Indole and benzimidazole inhibitors of factor Xa |
| JP2004517851A (ja) * | 2000-12-27 | 2004-06-17 | バイエル アクチェンゲゼルシャフト | 甲状腺受容体のリガンドとしてのインドール誘導体 |
| IL157031A0 (en) * | 2001-02-08 | 2004-02-08 | Karobio Ab | Thyroid receptor ligands |
| GB0224557D0 (en) | 2002-10-22 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
| AR042206A1 (es) * | 2002-11-26 | 2005-06-15 | Novartis Ag | Acidos fenilaceticos y derivados |
| CA2511214C (en) | 2002-12-20 | 2012-12-18 | Tularik, Inc. | Asthma and allergic inflammation modulators |
| WO2005010202A2 (en) * | 2003-07-16 | 2005-02-03 | Ligand Pharmacueticals Incorporated | PHENYL ACETIC ACID DERIVATIVES AS HEPATOCYTE NUCLEAR FACTOR 4α (HNF-4α) MODULATOR COMPOUNDS |
| SE0302232D0 (sv) * | 2003-08-18 | 2003-08-18 | Astrazeneca Ab | Novel Compounds |
| EP1660504B1 (en) * | 2003-08-29 | 2008-10-29 | Pfizer Inc. | Thienopyridine-phenylacet amides and their derivatives useful as new anti-angiogenic agents |
| WO2005054176A1 (en) | 2003-11-25 | 2005-06-16 | Eli Lilly And Company | Peroxisome proliferator activated receptor modulators |
-
2008
- 2008-04-30 US US12/113,121 patent/US7960567B2/en active Active
- 2008-05-01 MX MX2009011412A patent/MX2009011412A/es active IP Right Grant
- 2008-05-01 JP JP2010506316A patent/JP5537417B2/ja not_active Expired - Fee Related
- 2008-05-01 CA CA2685215A patent/CA2685215C/en not_active Expired - Fee Related
- 2008-05-01 ES ES08743426T patent/ES2402987T3/es active Active
- 2008-05-01 WO PCT/US2008/005611 patent/WO2008137027A2/en not_active Ceased
- 2008-05-01 EP EP08743426A patent/EP2164828B1/en active Active
- 2008-05-01 AU AU2008248201A patent/AU2008248201B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010526069A5 (enExample) | ||
| JP6193922B2 (ja) | ハロアルキルヘテロアリールベンズアミド化合物 | |
| TWI382984B (zh) | 雜環化合物 | |
| JP6861703B2 (ja) | Ｔｇｒ５修飾物質およびその使用方法 | |
| JP2009521399A5 (enExample) | ||
| CA2511214A1 (en) | Asthma and allergic inflammation modulators | |
| JP2019504899A5 (enExample) | ||
| CN105793236B (zh) | 二甲基苯甲酸化合物 | |
| RU2006113638A (ru) | Антагонисты рецептора тромбина | |
| JP2015503505A5 (enExample) | ||
| TW200530195A (en) | Benzimidazole derivatives: preparation and pharmaceutical applications | |
| JP2011526926A5 (enExample) | ||
| JP2010501478A5 (enExample) | ||
| JP2005517696A (ja) | バルサルタンの塩類 | |
| CN116547288A (zh) | 用于治疗和/或预防netosis的方法和化合物 | |
| JP2013528656A5 (enExample) | ||
| BRPI0615690B1 (pt) | compostos heterocíclicos de hidroxamato, seus usos e composição farmacêutica | |
| JP2018508513A5 (enExample) | ||
| JPWO2015147020A1 (ja) | アミド化合物 | |
| WO2022120118A1 (en) | Novel ripk1 kinase targeting protacs and methods of use thereof | |
| JP2011519845A5 (enExample) | ||
| JP2017509611A5 (enExample) | ||
| JP2010535156A (ja) | ウイルスポリメラーゼ阻害剤 | |
| WO2007062678A1 (en) | Phenoxyacetic acid derivatives as crth2 receptor ligands | |
| CN109790170B (zh) | Gaba(a)受体调节剂和控制哮喘中气道高反应性和炎症的方法 |